IRIS Accounts Production v26.1.10.61 06509477 Board of Directors 30.12.24 29.12.25 29.12.25 4/6/2026 true false true false false false true false Auditors Opinion Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh065094772024-12-29065094772025-12-29065094772024-12-302025-12-29065094772023-12-29065094772023-12-302024-12-29065094772024-12-2906509477ns15:EnglandWales2024-12-302025-12-2906509477ns14:PoundSterling2024-12-302025-12-2906509477ns10:Director12024-12-302025-12-2906509477ns10:PrivateLimitedCompanyLtd2024-12-302025-12-2906509477ns10:SmallEntities2024-12-302025-12-2906509477ns10:Audited2024-12-302025-12-2906509477ns10:SmallCompaniesRegimeForDirectorsReport2024-12-302025-12-2906509477ns10:SmallCompaniesRegimeForAccounts2024-12-302025-12-2906509477ns10:FullAccounts2024-12-302025-12-290650947712024-12-302025-12-2906509477ns10:OrdinaryShareClass12024-12-302025-12-2906509477ns10:Director22024-12-302025-12-2906509477ns10:Director32024-12-302025-12-2906509477ns10:RegisteredOffice2024-12-302025-12-2906509477ns5:CurrentFinancialInstruments2025-12-2906509477ns5:CurrentFinancialInstruments2024-12-2906509477ns5:Non-currentFinancialInstruments2025-12-2906509477ns5:Non-currentFinancialInstruments2024-12-2906509477ns5:ShareCapital2025-12-2906509477ns5:ShareCapital2024-12-2906509477ns5:SharePremium2025-12-2906509477ns5:SharePremium2024-12-2906509477ns5:RetainedEarningsAccumulatedLosses2025-12-2906509477ns5:RetainedEarningsAccumulatedLosses2024-12-2906509477ns5:ComputerSoftware2024-12-302025-12-2906509477ns5:IntangibleAssetsOtherThanGoodwill2024-12-2906509477ns5:IntangibleAssetsOtherThanGoodwill2024-12-302025-12-2906509477ns5:IntangibleAssetsOtherThanGoodwill2025-12-2906509477ns5:IntangibleAssetsOtherThanGoodwill2024-12-2906509477ns5:LeaseholdImprovements2024-12-2906509477ns5:PlantMachinery2024-12-2906509477ns5:FurnitureFittings2024-12-2906509477ns5:ComputerEquipment2024-12-2906509477ns5:LeaseholdImprovements2024-12-302025-12-2906509477ns5:PlantMachinery2024-12-302025-12-2906509477ns5:FurnitureFittings2024-12-302025-12-2906509477ns5:ComputerEquipment2024-12-302025-12-2906509477ns5:LeaseholdImprovements2025-12-2906509477ns5:PlantMachinery2025-12-2906509477ns5:FurnitureFittings2025-12-2906509477ns5:ComputerEquipment2025-12-2906509477ns5:LeaseholdImprovements2024-12-2906509477ns5:PlantMachinery2024-12-2906509477ns5:FurnitureFittings2024-12-2906509477ns5:ComputerEquipment2024-12-2906509477ns5:CostValuation2024-12-2906509477ns5:WithinOneYearns5:CurrentFinancialInstruments2025-12-2906509477ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-2906509477ns5:Non-currentFinancialInstruments2024-12-302025-12-2906509477ns10:OrdinaryShareClass12025-12-29
REGISTERED NUMBER: 06509477 (England and Wales)















SCINOMED LTD

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 29 DECEMBER 2025






SCINOMED LTD (REGISTERED NUMBER: 06509477)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 DECEMBER 2025




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


SCINOMED LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 29 DECEMBER 2025







DIRECTORS: Mr A P Lane
Mr M Hauck
Mr J Simkins





REGISTERED OFFICE: Windsor House
Cornwall Road
Harrogate
HG1 2PW





REGISTERED NUMBER: 06509477 (England and Wales)





AUDITORS: DSC Accountants Ltd
Chartered Accountants
Statutory Auditors
Tattersall House
East Parade
Harrogate
North Yorkshire
HG1 5LT

SCINOMED LTD (REGISTERED NUMBER: 06509477)

BALANCE SHEET
29 DECEMBER 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 440,037 543,570
Tangible assets 5 398,656 456,000
Investments 6 1,965,656 1,965,656
2,804,349 2,965,226

CURRENT ASSETS
Stocks 18,432 1,073,055
Debtors 7 12,885,386 9,121,602
Prepayments and accrued income 377,379 683,122
Cash at bank 44,720 101,764
13,325,917 10,979,543
CREDITORS
Amounts falling due within one year 8 218,355 460,259
NET CURRENT ASSETS 13,107,562 10,519,284
TOTAL ASSETS LESS CURRENT
LIABILITIES

15,911,911

13,484,510

CREDITORS
Amounts falling due after more than one year 9 (26,455,817 ) (24,323,373 )

ACCRUALS AND DEFERRED INCOME (86,019 ) (120,249 )
NET LIABILITIES (10,629,925 ) (10,959,112 )

CAPITAL AND RESERVES
Called up share capital 10 800,000 800,000
Share premium 5,715,000 5,715,000
Retained earnings (17,144,925 ) (17,474,112 )
SHAREHOLDERS' FUNDS (10,629,925 ) (10,959,112 )

SCINOMED LTD (REGISTERED NUMBER: 06509477)

BALANCE SHEET - continued
29 DECEMBER 2025


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 4 June 2026 and were signed on its behalf by:





Mr A P Lane - Director


SCINOMED LTD (REGISTERED NUMBER: 06509477)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 DECEMBER 2025

1. STATUTORY INFORMATION

Scinomed Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Preparation of consolidated financial statements
The financial statements contain information about Scinomed Ltd as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Going concern
At the balance sheet date, the company had net liabilities of £10,629,925.

The parent undertaking and ultimate parent undertaking have confirmed that they will provide further financial support to the company as required to enable it to meet its liabilities as and when they fall due for at least twelve months from the date of approval of the financial statements of the company. Consequently, the financial statements have been prepared on a going concern basis.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Turnover is recognised on despatch at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Research & development costs
Where research and development costs are capitalised, amortisation is provided at the following annual rate in order to write off each asset over its estimated useful life.

Research and development costs - between 10% and 20% on cost

Tangible fixed assets
Tangible fixed assets are initially measured at cost. After initial recognition tangible fixed assets are measured at cost less accumulated depreciation and any impairment losses.

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Improvements to property - 10% on cost
Plant and machinery - 20% on cost
Fixtures and fittings - 10% on cost
Office Equipment - 25% on cost

Investments in subsidiaries
Investments in subsidiary undertakings are initially recognised at cost. After initial recognition, investments in subsidiary undertakings are measured at cost less any accumulated impairment losses.

SCINOMED LTD (REGISTERED NUMBER: 06509477)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 29 DECEMBER 2025

2. ACCOUNTING POLICIES - continued

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Cost is derived as the total free on board cost including freight charges.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Debtors
Short term debtors are measured at transaction price, less any impairment.

Cash at bank and in hand
Cash at bank and in hand represents cash and short-term highly liquid funds.

Creditors
Creditors are recognised when the company has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors are normally recognised at their settlement amount after allowing for any discounts due.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 6 (2024 - 6 ) .

SCINOMED LTD (REGISTERED NUMBER: 06509477)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 29 DECEMBER 2025

4. INTANGIBLE FIXED ASSETS
Other
intangible
assets
£   
COST
At 30 December 2024 1,274,739
Additions 24,174
At 29 December 2025 1,298,913
AMORTISATION
At 30 December 2024 731,169
Charge for year 127,707
At 29 December 2025 858,876
NET BOOK VALUE
At 29 December 2025 440,037
At 29 December 2024 543,570

5. TANGIBLE FIXED ASSETS
Improvements Fixtures
to Plant and and Office
property machinery fittings Equipment Totals
£    £    £    £    £   
COST
At 30 December 2024 1,579 648,304 18,934 39,861 708,678
Additions - 26,453 - 19,500 45,953
Disposals - (2,062 ) - - (2,062 )
At 29 December 2025 1,579 672,695 18,934 59,361 752,569
DEPRECIATION
At 30 December 2024 1,579 204,091 12,392 34,616 252,678
Charge for year - 92,810 1,590 7,797 102,197
Eliminated on disposal - (962 ) - - (962 )
At 29 December 2025 1,579 295,939 13,982 42,413 353,913
NET BOOK VALUE
At 29 December 2025 - 376,756 4,952 16,948 398,656
At 29 December 2024 - 444,213 6,542 5,245 456,000

SCINOMED LTD (REGISTERED NUMBER: 06509477)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 29 DECEMBER 2025

6. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 30 December 2024
and 29 December 2025 1,965,656
NET BOOK VALUE
At 29 December 2025 1,965,656
At 29 December 2024 1,965,656

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade debtors - 29,296
Amounts owed by group undertakings 12,876,798 8,726,251
Other debtors 8,588 366,055
12,885,386 9,121,602

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade creditors 66,830 331,574
Taxation and social security 144,877 18,080
Other creditors 6,648 110,605
218,355 460,259

9. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2025 2024
£    £   
Amounts owed to group undertakings 26,455,817 24,323,373

The loans are unsecured with no set repayment date. A market rate of interest is payable on the loans.

10. CALLED UP SHARE CAPITAL

Allotted and issued:
Number: Class: Nominal 2025 2024
value: £    £   
800,000 Share capital 1 £1 800,000 800,000

SCINOMED LTD (REGISTERED NUMBER: 06509477)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 29 DECEMBER 2025

11. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Graham French (Senior Statutory Auditor)
for and on behalf of DSC Accountants Ltd

12. ULTIMATE CONTROLLING PARTY

The controlling party is International Investments II Limited, a company incorporated in Hong Kong.